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Background: The newly released 450k DNA methylation array from Illumina, Inc. offers the possibility to analyze
more than 480,000 individual CpG sites in a user friendly standardized format. In this study the relationship between
the β-values provided by the Illumina, Inc. array for each individual CpG dinucleotide and the quantitative
methylation levels obtained by pyrosequencing were analyzed. In addition, the representation of microRNA genes
and imprinted loci on the Illumina, Inc. array was assessed in detail. Genomic DNA from 4 human breast cancer cell
lines (IPH-926, HCC1937, MDA-MB-134, PMC42) and 18 human breast cancer specimens as well as 4 normal
mammary epithelial fractions was analyzed on 450k DNA methylation arrays. The β-values for 692 individual CpG
sites from 62 different genes were cross-validated using conventional quantitative pyrosequencing.
Findings: The newly released 450k methylation array from Illumina, Inc. shows a high concordance with
quantitative pyrosequencing if identical CpG sites are analyzed in cell lines (Spearman r = 0.88, p< 0.0001), which is
somewhat reduced in primary tumor specimens (Spearman r = 0.86, p< 0.0001). 80.7% of the CpG sites show an
absolute difference in methylation level of less than 15 percentage points. If different CpG sites in the same CpG
islands are targeted the concordance is lower (r = 0.83 in cell lines and r = 0.7 in primary tumors). The number of
CpG sites representing microRNA genes and imprinted loci is very heterogeneous (range: 1 – 70 CpG sites for
microRNAs and 1 – 288 for imprinted loci).
Conclusions: The newly released 450k methylation array from Illumina, Inc. provides a genome-wide quantitative
representation of DNA methylation aberrations in a convenient format. Overall, the congruence with
pyrosequencing data is very good. However, for individual loci one should be careful to translate the β-values
directly into percent methylation levels.Background
The genome-wide assessment of DNA methylation patterns
becomes more and more important in cancer research
[1,2]. However, so far the comprehensive analysis of all po-
tential CpG sites in the human genome, as demonstrated
for the first time in 2009 by Lister et al. [3] is - in terms of
costs per sample and required data processing resources -
well beyond the options of most research groups. Therefore,
various protocols have been developed to analyze a repre-
sentative subset of the human genome [4,5]. The most* Correspondence: Lehmann.Ulrich@MH-Hannover.de
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reproduction in any medium, provided the origrecent addition to this arsenal of methods is the 450k DNA
methylation array from Ilumina. Inc, which measures in
parallel the methylation of approximately 480,000 CpG sites
across the human genome. It was attempted to cover all
known protein coding genes as well as a fairly large number
of non-coding RNA genes and imprinted loci. Based on the
well-established and widely used Infinium technology [6]
this array platform promises an easy-to-use, standardized,
and cost effective format for the analysis of a representative
subset of the human methylome.
The array design, content, and technical performance
are well described in two recent publications [7,8]. How-
ever, both publications are not independent from the
manufacturer and so far only limited data are availablel Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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other quantitative methods well established in the field
of DNA methylation research. Dedeurwaerder et al. [9]
compared the methylation level of altogether 15 CpG
sites in 2 cell line samples (30 measurements) and 4
CpG sites in 6 primary samples (6 measurements) with
quantitative pyrosequencing. An analysis of the represen-
tation of genes important in tumor biology (measured as
number of CpG sites per gene) on the 450k array has
not yet been published so far. Therefore, we compared
the methylation level of altogether 692 individual CpG
sites from 62 different genes in a series of cell lines and
primary human tissue samples and analyzed in detail
how microRNA genes and imprinted loci are represented
on the array.
Findings
It is expected that the 450k DNA methylation array from
Illumina, Inc. will be as widely used as its predecessor, the
27k methylation array, and will thereby influence the
methylation field to a great extent. Therefore, careful and
critical analysis of the strengths and weaknesses of this
methodology as early as possible is of great importance.
Cross-validation of 450k methylation array and
pyrosequencing
For the cross-validation of the 450k array we selected
quantitative pyrosequencing which is a well-established
and widely used method in the field of DNA methylation
research. Several groups, including our own [10,11],
could show that for many loci pyrosequencing provides a
very good quantitative measure of the methylation level
at individual CpG sites (see also Additional file 1). The
comparison of β-values and pyrosequencing results was
performed separately for cell lines and primary human
tissue samples and included altogether 692 individual
CpG dinucleotides (340 in cell lines and 352 in primary
specimens). From the 352 individual CpG sites compared
one-by-one in primary tumor specimens 80.3% show a
difference in methylation level of less than 15 percentage
points. If 10 percentage points are chosen as threshold,
60.5% of all data points are within this range of agree-
ment. The corresponding numbers for the analyses in
cell lines are very similar: 77.4% and 63.8%, respectively.
Figure 1 A) and B) show a very good concordance be-
tween both methods (cell lines: Spearman r = 0.88, pri-
mary tissue Spearman r = 0.86). However, the calculation
of a correlation coefficient or a regression coefficient can
be misleading, because the scatter plots are dominated
by two agglomerations of data points near the origin of
the scatter plot and near the 100% value. In between, the
accordance between both methods is reduced. This can
be seen more clearly in the corresponding Bland-Altman-
Plots (Figure 1 C) and D)). In a Bland-Altman-Plotthe difference between the two methods under study is
plotted against the mean of both methods for every indi-
vidual pair of measurements. The interval of the mean of
the difference +/− two times the standard deviation
defines the 95% interval of the limits of agreement. In this
kind of plot it is much more obvious that the data points
become more dispersed in the range of 25 – 75% methy-
lation (indicating less concordance). All data points out-
side the 95% limits of agreement (marked by the dotted
lines) are lying in this middle region. If the CpG sites tar-
geted by the pyrosequencing assay and the 450k array are
not identical but from the same CpG islands, the agree-
ment is - as expected – reduced (Spearman r = 0.83 for
cell lines and r = 0.71 for primary specimens, see Add-
itional file 2).
Common SNPs could be excluded as a major source of
the discrepancies between pyrosequencing and 450k
methylation array. All data points above or below the
limits of agreement in Figure 1 C) and D) were checked
for the presence of SNPs in the corresponding probes on
the 450k array and also in the pyrosequencing assays. As
a control 20 data points with very high concordance
were randomly selected and checked for the potential
presence of SNPs. No clear correlation between the level
of agreement and the potential presence of SNPs could
be identified.
If a threshold of 10 to 20% methylation is chosen for
scoring CpG sites as “hypermethylated”, this reduced ac-
cordance in the middle range of methylation levels (25 –
75%) is not a problem at all. However, if cluster analyses
are performed with the β-values for subsets of probes,
which show intermediate methylation levels, results
should be interpreted carefully.
If only cell line DNA samples are used for the evaluation
and comparison of methods for the analysis of DNA
methylation a certain bias is introduced because the vast
majority of loci display a clear dichotomous distribution in
cell lines: either no or very low level DNA methylation or
very high, nearly complete methylation. Therefore, any
scatter plot (and subsequent calculations of correlation or
regression coefficients) illustrating the comparison of
methods or samples is dominated by two populations of
data points (i.e., close to 0 and close to 1 or 100%). This
can easily be verified by visual inspection of Fig. 6 A) and
B) in Sandoval et al. [8], Fig. 4 in Bibikova et al., [7], Fig. 4
A) in Dedeurwaerder et al. [9], and our own Figure 1.
The first publication about the 450k array from
Sandoval et al. [8] in collaboration with Illumina, Inc.
gives a very good overview of the loci covered and the
classes of CpG sites included in the 450k array design.
However, it did not cross-validate the results directly
with another method but only indirectly by comparing
the 450k array with the well-established GoldenGateW





























































Figure 1 Cross-validation of 450k methylation array and quantitative pyrosequencing. Shown are scatter plots for the methylation values
obtained by pyrosequencing (x-axis) and the β-values obtained from the 450k array for identical CpG sites. A) cell lines (Spearman r = 0.88, linear
regression r2 = 0.89, slope: 0.89, 95% confidence interval: 0.86 – 0.93), B) primary human tumor tissues (Spearman r = 0.85, linear regression r2 = 0.77,
slope: 0.86, 95% confidence interval: 0.81 – 0.91). Each dot in the figure represents the comparison of % methylation according to pyrosequencing
versus the β-value for a single CpG site in one sample. C) and D) corresponding Bland-Altman plots. The difference between both methods for
every individual measurement is plotted against the mean of both methods. The mean of the differences +/− two times the standard deviation
denotes the 95% range for the limits of agreement (marked by the horizontal dotted lines). For the construction of these plots the β-values have
been multiplied by the factor 100 in order to obtained data sets of the same size range. The coordinates of the individual CpG sites analyzed in
this comparison are compiled in Additional file 3.
Roessler et al. BMC Research Notes 2012, 5:210 Page 3 of 7
http://www.biomedcentral.com/1756-0500/5/210publication about the 450k array exclusively from Illu-
mina, Inc. [7] a cross-validation with deep-sequencing
for two samples is reported. Due to the high number of
data points (189,000 and 167,000, respectively) the cor-
relation seems to be extremely good (r2 = 0.96). But a
more careful inspection of Figure 5B from this publica-
tion shows that the data points form a “broad band”,
which is 30 – 40 percentage points wide, meaning that
many measurements differ by 30 – 40 percentage points.
There are an unidentifiable number of measurements
with no methylation in the sequencing analysis and up
to 50% methylation level according to the array analysis.
This is indicated by the black line at the bottom of Fig-
ure 5 B) parallel to the x-axis at 0.0 methylation value
according to sequencing (y-axis) and ranging from a β-
value of 0.0 to a β-value of approx. 0.5 at the x-axis. The
same phenomenon can be seen at the upper limit of the
scale at the top of Figure 5 B): A black line parallel to
the x-axis at 1.0 methylation according to sequencing
and ranging from a β-value of approx. 0.4 to a β-value of
1.0 indicating 100% methylation according to sequencing
and 40 – 100% according to array analysis. This clearly
shows in line with our results that whereas overall theconcordance is very high the derivation of methylation
levels of individual genes or loci from β-values might be
uncertain and requires independent validation.
Comparison of Infinium I and Infinium II assays
A potential problem of the 450k methylation array is
the fact that it combines two different assays on a single
array, namely the Infinium I and Infinium II technology
(see Figure 1 in ref. [7] or Figure 2 in ref. [9] for a very
good illustration of the principal of the two different
assays). Dedeurwaerder et al. [9] describe in detail the ef-
fect of these two different assays on the β-value distribu-
tion (Fig. 1 in ref. [9]) observed now by many users in the
DNA methylation community. Therefore, we analyzed all
correlations between β-values and pyrosequencing results
separately for Infinium I and II assays. Overall, the agree-
ment between pyrosequencing and Infinium I and II, re-
spectively, are very similar for both cell lines and primary
patient samples (see Additional file 4). The above men-
tioned observation, that the concordance of both methods
in the range of 25 – 75% methylation is reduced, affects
both assay types to a similar extent. Our re-analysis of the
data presented by Dedeurwaerder et al. [9] shows that the
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prove the congruence (see Additional file 5). These
authors performed also a much more limited comparison
of pyrosequencing and the 450k methylation array, espe-
cially for primary human tissue samples: The results of
only six measurements are presented (Fig 5 B in Dedeur-
waerder et al. [9]), in comparison to 352 measurements in
primary tissues samples evaluated by us.
The reduced concordance in primary patient samples
might be due to the heterogeneous methylation patterns
frequently encountered in primary samples compared with
cell lines. As described in detail by Bibikova et al. [7] in the
introduction section of their publication the basic assump-
tion for the Infinium assay design is, that adjacent CpG
sites display very similar methylation levels, thereby enab-
ling the selection of closely spaced probes including poten-
tial methylation sites in their binding site. However, the
two studies cited by Bibikova et al. as supporting this as-
sumption [12,13] analyzed healthy normal tissue samples
or healthy primary cell samples but not tumor tissue sam-
ples. Since many genes and loci show extensive heterogen-
eity in methylation patterns in tumor cells (e.g., p16INK4A
in HCC [11]), the methylation level of individual CpG sites
might be assessed incorrectly.
Representation of microRNA genes and imprinted loci
Since we have a long standing interest in epigenetic regula-
tion of microRNA genes [14] and imprinted loci [15] the
representation of these two important classes of non-protein
coding genes with pleiotropic regulatory functions was
assessed in detail for several microRNA genes already under
investigation in our group [11,14]. The number of CpG sites
analyzed is in general comparable to the number of CpG
sites included in pyrosequencing assays (i.e., 4 – 13 CpGFigure 2 Representation of the SNRNP locus on the 450k methylation
four differentially methylated regions (red lollipops). Below each region the
on Robertson 2005 [16] and references therein).sites). However, due to the assay design the CpG sites cov-
ered are spread over a much larger region: 900-1500 bp, in
comparison to 50 – 100 bp for an average pyrosequencing
assay. Whether this is an advantage or disadvantage depends
on the circumstances. The often very heterogeneous methy-
lation patterns encountered especially in primary tumor spe-
cimens might be better recognized by the analysis of a
continuous stretch of CpG sites as with pyrosequencing or
conventional bisulfite sequencing. On the other hand, the
spreading of CpG sites analyzed on the 450k array might
give a better representation of the methylation status of a
whole genomic locus.
A few microRNA loci are very well represented on
the 450k array (e.g., hsa-mir-1256 with 34 CpG sites and
hsa-miR-548H4 with 70 CpG sites) despite the fact that so
far only very limited data about epigenetic regulation or the
cellular function of these microRNAs are available (status:
January 31th, 2012). Notwithstanding sparse published func-
tional evidences the miR-548 family is represented by
altogether 252 CpG sites. However, this might be advanta-
geous for future studies focusing on these microRNAs.
The representation of imprinted loci is on average much
better. Up to 180 CpG sites cover a single differentially
methylated region. The analysis of the following 11 loci
revealed a very good representation of these imprinted loci
(in terms of number and location of CpG sites assayed on
the 450k array): IGF2, IGF2R, SNRPN, CDKN1C, MEG3/
DLK1, GNAS, PEG3, PLAGL1(ZAC), PEG10, MEST(PEG1),
GRB10. Figure 2 shows as an example how many CpG sites
within the four imprint control regions of the SNRPN locus
on chr. 15q11-13 are measured using the 450k array.
The concordance between the β-values, our pyrosequen-
cing results, and the pyrosequencing values reported by
Woodfine et al. [17] for four imprinted loci is shown inarray. This figure shows the organization of the SNRPN locus with the
number of CpG sites represented on the 450k array is indicated (based
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ments (9 different CpG sites in four samples).
Despite the above discussed reduced agreement be-
tween both methods in the middle range of methylation
levels for some loci the results in Figure 3 demonstrate a
very good concordance for four imprinted loci in normal
primary mammary tissue samples between the pyrose-
quencing data from two independent laboratories and
450k DNA methylation array data.
A potential pitfall of the analysis of 450k array data is
the annotation of probes which is not really consistent and
straightforward in the small set of microRNA loci which
we investigated in detail. A purely gene name-based search
will miss many microRNA gene associated CpG sites due
to inconsistent nomenclature. The assignment of a given
CpG dinucleotide to a microRNA is still very difficult or
impossible due to the lack of knowledge about microRNA
gene promoters and the primary microRNA transcripts
and due to the fact that many microRNAs are located
within protein coding genes. Nevertheless, several incon-
sistencies in nomenclature could be eliminated in the next
version of the probe identification sheet.
It should also be mentioned that a major limitation of
all bisulfite treatment based methodologies is the inabil-
ity to differentiate between methylcytosine and hydroxy-
methylcytosine [18-20]. The latter one is playing a
crucial role at least in developmental biology.
Conclusion
The newly released 450k methylation array from Illumina,
Inc. provides a genome-wide quantitative representation of
DNA methylation aberrations in a convenient format. For
the majority of CpG sites the β-values represent a very good
measure of the methylation status. However, for individual
loci the direct transformation of β-values into methylation
levels should be handled with care and validated by an inde-
pendent method. The representation and annotation of
functionally important loci could be improved in future ver-
sions of the array.Figure 3 Comparison of methylation levels for four imprinted loci. Th
four healthy normal mammary tissue samples using pyrosequencing and th
indicating the standard deviation. For KvDMR six CpG sites represented on
remaining three loci only one CpG site was also measured by the pyrosequ
Woodfine et al. [17] are incorporated. These data are also obtained by pyro
standard deviations are reported for these data.Methods
Tissue specimens and bisulfite modification of DNA
All primary human tissue samples were retrieved from
the archive of the Institute of Pathology, Hanover Med-
ical School (Germany) and analyzed anonymously
following the guidelines of the local Ethics committee
("Ethik-Kommission der Medizinischen Hochschule
Hannover", head: Prof. Dr. Tröger). Tumor cell content
was determined to be greater than 70%. DNA was isolated
by digestion with Proteinase K (Merck, Darmstadt,
Germany) followed by phenol/chloroform extraction from
a total of 22 specimens (Additional file 6). Genomic DNA (1
μg) from tumor specimens was treated with sodium bisulfite
using the EZ DNA Methylation™ kit (ZymoResearch, Irvine,
CA, USA) following the protocol supplied by the manufac-
turer with the exception of eluting the treated DNA with
distilled water instead of using the provided elution buffer.
Cell lines HCC1937, MDA-MB-134, and PMC42 were
purchased from ATCC and cultivated following the provided
protocols. The cell line IPH-926 was established in our insti-
tution and is described comprehensively elsewhere [21].
Methylation analysis using the 450k array
DNA methylation analysis using the Infinium Human-
Methylation450k BeadChip (Illumina, Inc., San Diego,
CA, USA) was performed according the manufactures'
instruction. The HumanMethylation450 BeadChip was
developed to assay more than 480,000 CpG sites selected
CpG loci in parallel (Bibikova et al., 2011). DNA methy-
lation data were processed using GenomeStudio software
(ver. 2011.1; Illumina, Inc.) applying the default settings.
Methylation analysis using pyrosequencing
PCR products were generated in a 25 μL reaction volume
with 400 nmol/L of forward, 40 nmol/L reverse and 400
nmol/L universal biotinylated primers, 200 μmol/L of each
dNTP, 1.5 mmol/L or 2.5 mmol/L MgCl2 (see Additional
file 7 for all primer sequences and reaction conditions), 1x
Platinum-Taq reaction buffer and 1.25 units PlatinumTaq™e methylation level of GNAS, KvDMR, RB1, and DIRAS3 was measured in
e 450k methylation array. Shown are the mean values, the error bars
the 450k array are measured by the pyrosequencing assay. For the
encing assay. In addition the data from Supplementary Table S2 from
sequencing from 3 or 6 normal mammary tissue specimens. No
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for 5 minutes, followed by 45 cycles with denaturation at
95°C for 30 seconds, annealing at 55°C or 60°C for 45 sec-
onds, and elongation at 72°C for 30 seconds finished with
1 cycle final elongation at 72°C for 5 minutes. The reverse
primer is tagged by a sequence recognized by the universal
primer. Therefore, a single (expansive) biotinylated primer
can be used for all different gene-specific assays [22].
PCR products (5–20 μL) were added to a mix consisting
of 3 μL Streptavidin Sepharose HP™ (Amersham Bios-
ciences, Freiburg, Germany) and 47 μL binding buffer (Qia-
gen, Hilden, Germany) and mixed at 1200 rpm for 5
minutes at room temperature.
Using the Vacuum Prep Tool™ (Qiagen, Hilden, Ger-
many), single-stranded PCR products were prepared fol-
lowing the manufacturer's instructions. The sepharose
beads with the single stranded templates attached were
released into a PSQ 96 Plate Low™ (Qiagen, Hilden, Ger-
many) containing a mix of 12 μL annealing buffer (Qiagen,
Hilden, Germany) and 500 nmmol/L of the corresponding
sequencing primer (see Additional file 7). Pyrosequencing™
reactions were performed in a PyroMark MD System (Qia-
gen, Hilden, Germany) according to the manufacturer's
instructions using the PyroGold SQA™ Reagent Kit (Qia-
gen, Hilden, Germany). CpG site quantification was per-
formed using the methylation Software Pyro Q-CpG™.
Statistical analyses
All calculations were performed using GraphPad Prisms5
software. p-values smaller than 0.5 were considered sta-
tistically significant.
For the comparison of the two methods Bland-Altman-
Plots were generated [23]. In these plots the difference of
two methods is plotted against the average of both
methods. A comprehensive description of this type of
data presentation by Altman and Bland ("Measurements
in Medicine: the Analysis of Method Comparison Stud-
ies", The Statistician 32 (1983) 307 – 317) can be found
freely available at: https://person.hst.aau.dk/slc/Teach-
ing/Papers/BlandAltman83.pdf.(availabilitychecked: 17th
February 2012). In order to obtain data sets of comparable
range for the construction of the Bland-Altman-plots, the
β-values were transformed using the following equation:
β-value x 100=% methylation (Illumina).Additional files
Additional file 1: Linearity of pyrosequencing for 4 different genes (SFRP1,
APC, DAPK, KvDMR).
Additional file 2: Comparison of the concordance between pyrosequencing
and the 450k array if the same CpG island is analyzed. For this purpose the
mean methylation levels obtained by each method for a given CpG island
were compared. Indicated are correlation coefficients according to Spearman
(r) and linear regression coefficients (r2).Additional file 3: Coordinates for all individual CpG sites compared in
Figure 1.
Additional file 4: Comparison of the concordance between pyrosequencing
and the 450k array for Infinium I and II assays separately. Indicated are
correlation coefficients according to Spearman (r) and linear regression
coefficients (r2).
Additional file 5: Scatter plot (A) and Bland-Altman-Plots without (B) and
with (C) peak correction for the data from Dedeurwaerder et al. Table S2.
Additional file 6: Primary human specimens used in this study.
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